Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004102 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
A Phase 2 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00004102 is a Phase 2 study that has completed, run by NYU Langone Health.
The verdict
NCT00004102, a Phase 2 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Leucovorin may increase the effectiveness of fluorouracil by making tumor cells more sensitive to the drug. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy consisting of oxaliplatin, fluorouracil, and leucovorin in treating patients who have colorectal cancer.
Interventions
- DRUG FOLFOX regimen
- DRUG oxaliplatin
- DRUG fluorouracil
- DRUG leucovorin calcium
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004102
The ClinicalTrials.gov registry entry for NCT00004102 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which FOLFOX regimen is the first listed.
NCT00004102 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004102 about?
NCT00004102 is a clinical study titled "Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Leucovorin may increase the effectiveness of fluorouracil by making tumor cells more sensitive to the drug. PURPOSE: Phase ...
What is the current status of trial NCT00004102?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-01.
What interventions are being tested in trial NCT00004102?
The interventions under investigation include: FOLFOX regimen (DRUG), oxaliplatin (DRUG), fluorouracil (DRUG), leucovorin calcium (DRUG).
Who is sponsoring clinical trial NCT00004102?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.